This is the online version of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.
I am entirely enthralled by the World Cup. I am watching a ton of soccer on TV. I love the Tartan Army that has invaded Boston for Scotland’s games at Gillette Stadium. Tiny Cape Verde drawing mighty Spain was incredible. Messi, 39, playing in his sixth (!) World Cup, is still the GOAT.
And England still hasn’t played but will in a couple of hours, as I get this newsletter finished on Wednesday afternoon. Olé!
Programming note: This newsletter is taking a holiday next week but will be back in your inboxes July 2.
What Soon-Shiong says vs. what he has delivered
I’ve taken a good bit of heat (and hate) from online fans of Patrick Soon-Shiong who view the billionaire physician as a selfless scientist/entrepreneur trying to rid the world of cancer. That’s a laudable goal, of course, except Soon-Shiong’s proclamations are mostly fluff , financially self-serving and have led to FDA wrist-slapping .
A wide gap exists between what Soon-Shiong says his cancer drugs can achieve and what they actually do, based on real clinical evidence.
Pancreatic cancer is an instructive and presently relevant example. Long before Soon-Shiong became rich and famous, he treated diabetic patients with pancreas transplants and performed surgery on patients with pancreatic cancer. A desire to transform the treatment of pancreatic cancer with novel immunotherapies inspired Soon-Shiong’s “Bioshield” mission, according to his own treatise .
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
View All Plans
To read the rest of this story subscribe to STAT+.
Subscribe
Read the full article at STAT News →📄Source document: FDA actions related to Soon-Shiong's treatments
2 reports
STAT NewsIndependentCenter3 days agoThe article discusses recent developments in biotechnology, including Cambria's experimental longevity drug that mimics the effects of exercise. It also mentions other biotech news such as Enanta's RSV antiviral and Patrick Soon-Shiong's pancreatic cancer claims.
Bias read (Center): The article provides general information about biotechnology advancements without overtly favoring any particular political perspective. It mentions various companies and their developments but does not present biased language or one-sided sourcing.
STAT NewsIndependentCenter3 days ago STAT+: In pancreatic cancer, Patrick Soon-Shiong makes promises he has not keptThe article discusses Patrick Soon-Shiong, a billionaire physician and entrepreneur, and critiques the disparity between his public claims about his cancer treatments and the actual clinical outcomes supported by evidence. The piece highlights concerns regarding the efficacy of his cancer drugs, particularly in the context of pancreatic cancer, and references regulatory actions such as FDA interventions.
Bias read (Center): The article presents a critical perspective on Patrick Soon-Shiong's claims about his cancer treatments without overtly favoring any particular political stance. It focuses on the discrepancy between his public statements and clinical evidence, using factual information and referencing regulatory (e
Official sources cited
- government FDA actions related to Soon-Shiong's treatments
United States